| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/08941939.2012.664099 |
| P698 | PubMed publication ID | 22439833 |
| P2093 | author name string | Lorenzo Zaffiri | |
| Luis H Toledo-Pereyra | |||
| Jared Gardner | |||
| P2860 | cites work | To Stamp Out “So Terrible a Malady”: Bovine Tuberculosis and Tuberculin Testing in Britain, 1890–1939 | Q22251400 |
| The structure of cephalesporin C | Q24532910 | ||
| Extended-spectrum beta-lactamases: a clinical update | Q24534999 | ||
| New light on the history of penicillin | Q24806998 | ||
| Staphylococcus aureus infections | Q28131787 | ||
| Paul Ehrlich's magic bullets | Q28249801 | ||
| A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children | Q28336069 | ||
| The penicillins | Q28372068 | ||
| American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America | Q29391534 | ||
| Trends in infectious disease mortality in the United States during the 20th century | Q30233737 | ||
| Beta-Lactam antibiotics (1). | Q30462185 | ||
| Fourth generation cephalosporins in the antimicrobial chemotherapy of surgical infections | Q33840080 | ||
| The Nobel chronicles. 1939: Gerhard Domagk (1895-1964). | Q33852831 | ||
| Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations | Q33928681 | ||
| Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States | Q33929756 | ||
| Resistance to trimethoprim-sulfamethoxazole | Q33945728 | ||
| A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group | Q33979272 | ||
| Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. | Q54105670 | ||
| Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. The Streptococcus pneumoniae Working Group. | Q54106765 | ||
| The role of fourth-generation cephalosporins in the treatment of serious infectious diseases in hospitalized patients. | Q54134253 | ||
| CHANGING SUSCEPTIBILITY OF MENINGOCOCCI TO ANTIMICROBIAL AGENTS. | Q54504716 | ||
| Streptomycin and alternative agents for the treatment of tularemia: review of the literature. | Q55065686 | ||
| Microbiological studies on a new broad-spectrum penicilin, "Penbritin". | Q55545449 | ||
| Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department | Q55897489 | ||
| The First Use of Penicillin in the United States | Q56058949 | ||
| PARA-AMINOSALICYLIC ACID IN THE TREATMENT OF TUBERCULOSIS | Q57487402 | ||
| Aminoglycoside resistance in enterococci | Q34033627 | ||
| Amoxycillin: A review of its antibacterial and pharmacokinietic properties and therapeutic use | Q34192107 | ||
| Derivatives of cephalosporin C formed with certain heterocyclic tertiary bases. The cephalosporin C-A family | Q34247912 | ||
| The cephalosporin C nucleus (7-aminocephalosporanic acid) and some of its derivatives | Q34249178 | ||
| Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management | Q34361837 | ||
| From Atoxyl to Salvarsan: searching for the magic bullet | Q34443544 | ||
| Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin | Q34788301 | ||
| Quantitative Inhibition of Haemophilus influenzae by Trimethoprim/Sulfamethoxazole | Q34988516 | ||
| A practical guide to the treatment of complicated skin and soft tissue infections | Q35166376 | ||
| Treatment of streptococcal pharyngitis with amoxycillin once a day. | Q35187874 | ||
| Actinomycosis and nocardiosis. A review of basic differences in therapy | Q35534132 | ||
| Antibiotic susceptibility of group A streptococci: a 6-year follow-up study | Q35818190 | ||
| Amoxicillin Therapy of Acute Urinary Infections in Adults | Q36462690 | ||
| Prospective Comparison of Cefoxitin and Cefazolin in Infections Caused by Aerobic Bacteria | Q36466532 | ||
| Connection between trimethoprim-sulfamethoxazole use and resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis | Q36744739 | ||
| Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials | Q36931056 | ||
| National prevalence of methicillin-resistant Staphylococcus aureus in inpatients at US health care facilities, 2006. | Q37026172 | ||
| Cefepime: a reappraisal in an era of increasing antimicrobial resistance | Q37079350 | ||
| Antimicrobial resistance among enterococci | Q37328448 | ||
| Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins | Q37521777 | ||
| Randomised comparison of amoxycillin and erythromycin in treatment of genital chlamydial infection in pregnancy | Q37888058 | ||
| Degradation, structure and some derivatives of cephalosporin N. | Q39246774 | ||
| The treatment of malaria | Q39590029 | ||
| Use of pyrimethamine-sulfadoxine (Fansidar) in prophylaxis against chloroquine-resistant Plasmodium falciparum and Pneumocystis carinii | Q39763317 | ||
| Characteristics of children discharged from hospitals in the United States in 2000 with the diagnosis of acute rheumatic fever | Q39811242 | ||
| 6-APA and the development of the β-lactam antibiotics | Q40204193 | ||
| Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study. | Q40394181 | ||
| Epidemiology of group B streptococcal disease. Risk factors, prevention strategies, and vaccine development | Q40504897 | ||
| Landmark article May 13, 1950: Prevention of rheumatic fever. Treatment of the preceding streptococcic infection. By Floyd W. Denny, Lewis W. Wannamaker, William R. Brink, Charles H. Rammelkamp Jr. and Edward A. Custer | Q40815971 | ||
| Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications | Q40852647 | ||
| Antibiotic susceptibility of Streptococcus bovis and other group D streptococci causing endocarditis | Q40943020 | ||
| Piperacillin/tazobactam: a critical review of the evolving clinical literature | Q41125741 | ||
| Antimicrobial-drug resistance | Q41171288 | ||
| Methicillin-resistant staphylococci | Q41289007 | ||
| Effect of streptomycin on experimental tuberculosis in guinea-pigs | Q41827198 | ||
| Isolation of antibiotics from a species of Cephalosporium; cephalosporins P1, P2, P3, P4, and P5. | Q42951249 | ||
| Experiments on the degradation of cephalosporin C. | Q42977041 | ||
| Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections | Q43877159 | ||
| Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs | Q44235796 | ||
| History revisited-Prontosil red. | Q46749763 | ||
| Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer | Q48019587 | ||
| Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot | Q48104741 | ||
| Sir Edward Abraham's contribution to the development of the cephalosporins: a reassessment | Q48579553 | ||
| Giuseppe Brotzu and the discovery of cephalosporins | Q48771860 | ||
| Efficacy of trimethoprim-sulfamethoxazole for the prevention of bacterial infections in a randomized prophylaxis trial of patients with advanced HIV infection. | Q53878719 | ||
| P433 | issue | 2 | |
| P921 | main subject | antibiotic | Q12187 |
| antimicrobial agent | Q68541106 | ||
| P304 | page(s) | 67-77 | |
| P577 | publication date | 2012-04-01 | |
| P1433 | published in | Journal of Investigative Surgery | Q15749610 |
| P1476 | title | History of antibiotics. From salvarsan to cephalosporins | |
| P478 | volume | 25 |
| Q26740597 | Adapting Drug Approval Pathways for Bacteriophage-Based Therapeutics |
| Q99556611 | Affording autism an early brain development re-definition |
| Q50418390 | An agenda for 21st century neurodevelopmental medicine: lessons from autism |
| Q41986554 | Antibiotics, gut microbiome, and obesity. |
| Q38989893 | Antimicrobial peptides as natural bio-preservative to enhance the shelf-life of food |
| Q89598097 | Arsenic Toxicity: Molecular Targets and Therapeutic Agents |
| Q38770314 | Autophagy as a target for therapeutic uses of multifunctional peptides. |
| Q64109917 | Casticin-Induced Inhibition of Cell Growth and Survival Are Mediated through the Dual Modulation of Akt/mTOR Signaling Cascade |
| Q67227791 | Combating bacterial resistance by combination of antibiotics with antimicrobial peptides |
| Q35084162 | Cost-effectiveness and pricing of antibacterial drugs |
| Q40134888 | Evaluation of free or anchored antimicrobial peptides as candidates for the prevention of orthopaedic device-related infections. |
| Q92742561 | Evaluation of hypercalciuria in patients receiving intravenous Cefotaxime |
| Q38987535 | Genomic and functional techniques to mine the microbiome for novel antimicrobials and antimicrobial resistance genes |
| Q48202873 | History of antibiotics: from fluoroquinolones to daptomycin (Part 2). |
| Q37517286 | How to measure the impacts of antibiotic resistance and antibiotic development on empiric therapy: new composite indices |
| Q36153263 | New Structural Templates for Clinically Validated and Novel Targets in Antimicrobial Drug Research and Development. |
| Q60047629 | Obesity: A New Adverse Effect of Antibiotics? |
| Q57295053 | Resistance decay in individuals after antibiotic exposure in primary care: a systematic review and meta-analysis |
| Q41589017 | Specific disulfide cross-linking to constrict the mobile carrier domain of nonribosomal peptide synthetases |
| Q55006206 | Stability of ceftiofur sodium and cefquinome sulphate in intravenous solutions. |
| Q27683865 | Structure of a class III engineered cephalosporin acylase: comparisons with class I acylase and implications for differences in substrate specificity and catalytic activity |
| Q55082178 | Systematic detection of positive selection in the human-pathogen interactome and lasting effects on infectious disease susceptibility. |
Search more.